The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 20, 2025
Filed:
Dec. 26, 2023
Astellas Pharma Inc., Tokyo, JP;
National Cancer Center, Tokyo, JP;
Yoshiyuki Tenda, Tokyo, JP;
Masatoshi Yuri, Tokyo, JP;
Daisuke Yamajuku, Tokyo, JP;
Takeshi Tsutsumi, Tokyo, JP;
Yuko Kusuzaki, Tokyo, JP;
Hiroki Sasaki, Chuo-ku, JP;
Fumiko Chiwaki, Chuo-ku, JP;
Masayuki Komatsu, Chuo-ku, JP;
Astellas Pharma Inc., Tokyo, JP;
National Cancer Center, Tokyo, JP;
Abstract
An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.